Literature DB >> 26662468

Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey.

Yoshito Tsushima1, Tsuneo Ishiguchi2, Takamichi Murakami3, Hiromitsu Hayashi4, Katsumi Hayakawa5, Kunihiko Fukuda6, Yukunori Korogi7, Hideharu Sugimoto8, Yasuo Takehara9, Yoshifumi Narumi10, Yasuaki Arai11, Ryohei Kuwatsuru12, Kengo Yoshimitsu13, Kazuo Awai14, Masayuki Kanematsu15, Ryo Takagi4.   

Abstract

PURPOSE: To help establish consensus on the safe use of contrast media in Japan.
MATERIALS AND METHODS: Questionnaires were sent to accredited teaching hospitals with radiology residency programs.
RESULTS: The reply rate was 45.4% (329/724). For contrast-induced nephropathy (CIN), chronic and acute kidney diseases were considered a risk factor in 96.7 and 93.6%, respectively, and dehydration in 73.9%. As preventive actions, intravenous hydration (89.1%) and reduction of iodinated contrast media dose (86.9%) were commonly performed. For nephrogenic systemic fibrosis (NSF), chronic and acute kidney diseases were considered risk factors in 98.5 and 90.6%, respectively, but use of unstable gadolinium-based contrast media was considered a risk factor in only 55.6%. A renal function test was always (63.5% in iodinated; 65.7% in gadolinium) or almost always (23.1; 19.8%) performed, and estimated glomerular filtration rate (eGFR) was the parameter most frequently used (80.8; 82.6%). For the patients with risk factors for acute adverse reaction (AAR), steroid premedication or/and change of contrast medium were frequent preventive actions, but intravenous steroid administration immediately before contrast media use was still performed.
CONCLUSION: Our questionnaire survey revealed that preventive actions against CIN were properly performed based on patients' eGFR. Preventive actions against NSF and AAR still lacked consensus.

Entities:  

Keywords:  Contrast medium; Guideline; Japan; Questionnaire; Safety

Mesh:

Substances:

Year:  2015        PMID: 26662468     DOI: 10.1007/s11604-015-0505-3

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  3 in total

1.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

Review 2.  The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.

Authors:  Jean-Marc Idée; Nathalie Fretellier; Caroline Robic; Claire Corot
Journal:  Crit Rev Toxicol       Date:  2014-09-26       Impact factor: 5.635

3.  Are screening serum creatinine levels necessary prior to outpatient CT examinations?

Authors:  R B Tippins; W E Torres; B R Baumgartner; D A Baumgarten
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

  3 in total
  2 in total

Review 1.  Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions.

Authors:  Ezekiel Maloney; Ramesh S Iyer; Grace S Phillips; Shina Menon; John J Lee; Michael J Callahan
Journal:  Pediatr Radiol       Date:  2019-03-29

2.  Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.

Authors:  Yoshito Tsushima; Kazuo Awai; Gen Shinoda; Hiroyuki Miyoshi; Masayuki Chosa; Toshiyuki Sunaya; Jan Endrikat
Journal:  Jpn J Radiol       Date:  2018-09-19       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.